CoChat

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

Wu, Eric Q., Johnson, Scott, Beaulieu, Nicolas, Arana, Mateo, Bollu, Vamsi, Guo, Amy, Coombs, John, Feng, Weiwei, Cortes, Jorge · 2010 · Current Medical Research and Opinion

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Patients with chronic myeloid leukemia (CML) who do not adhere to treatment may experience suboptimal outcomes. OBJECTIVE: To examine the association between adherence with imatinib and direct healthcare costs and resource utilization in a large group of privately insured CML patients. PATIENTS AND METHODS: CML patients under age 65 were identified with ICD-9 code 205.1X using MarketScan Commercial Claims data between 1/1/02 and 7/31/08. Patients were required to be continuously enrolled in a private insurance plan during the baseline and study periods, defined respectively as the 4 months prior to and the 12 months following imatinib initiation. Non-adherence was evaluated by the medication possession ratio (MPR), defined as the fraction of days during the study period that patients had filled prescriptions for imatinib, and stratified into two groups (low MPR: <85%, high MPR: > or =85%). Costs, inpatient admissions, and hospital days were compared between high and low adherence groups using Wilcoxon tests. Regression models compared utilization and costs controlling for age, sex, CML severity, Charlson comorbidity index, baseline costs, and other factors. RESULTS: The study sample consisted of 592 patients, where 242 (40.9%) patients were classified with a low MPR, while 350 (59.1%) had a high MPR. Mean MPR was 79% (95% confidence interval 76-81%). Patients with a low MPR incurred more all-cause inpatient visits (4.1 vs. 0.4; p < 0.001) and all-cause inpatient days (14.8 vs. 1.8; p < 0.001). Regression models demonstrated a 283% increase (US$56 324; p < 0.001) in non-imatinib costs within the low- vs. high-MPR group. The generalizability of this study is limited by the use of a privately insured population under 65 years of age as well as by the limitations common to claims data analyses. CONCLUSIONS: Imatinib adherence is an important issue for patients and physicians. Better imatinib adherence was associated with significantly lower resource utilization and costs in CML patients, as lower imatinib costs in low MPR patients were more than offset by higher non-imatinib costs mostly driven by inpatient services.

Overview

Integrity signals

Registry

Crossref · 10.1185/03007990903396469

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Research works printed but not linked: 6

  1. Nowell PC, 1960, J Natl Cancer Inst, 25, 85
  2. Lee WC, 2006, Manag Care Interface, 19, 31
  3. Doti C, 2007, Blood (ASH Annual Meeting Abstracts), 110, Abstract 4553
  4. Cervantes F, 2003, Haematologica, 88, 1117
  5. Sikka R, 2005, Am J Manag Care, 11, 449
  6. Greenberg RN., 1984, Clin Ther, 6, 592

Cited by

See all 126

Metadata

Authors
Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J.
Affiliations
  • Analysis Group (United States) (US)
  • Novartis (United States) (US)
  • MD Anderson Cancer Center, Houston, TX
Corresponding author
Wu, Eric Q.
Venue
Current Medical Research and Opinion
Published
2009-11-11
Volume
26
Issue
1
Pages
61-69
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W1982993780
Cited by
126
References
48
Citations by year
2026: 4 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 5 · 2019: 10 · 2018: 3 · 2017: 16 · 2016: 4 · 2015: 10 · 2014: 14 · 2013: 15 · 2012: 13
FWCI
5.56
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of California, San Francisco
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords
chronic myeloid leukemia, imatinib, medication adherence, medication possession ratio, health care costs, healthcare resource utilization, hospitalization, length of hospital stay, privately insured patients, generalizability of findings, comorbidities
MeSH terms
Imatinib Mesylate, Antineoplastic Agents, Benzamides, Humans, Patient Compliance, Piperazines, Pyrimidines, Health Care Rationing, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Health Care Costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. https://app.cochat.ai/papers/10.1185/03007990903396469
The paper
Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J. (2010). Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Current Medical Research and Opinion. https://doi.org/10.1185/03007990903396469

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.